Cedax was originally discovered by Shionogi and Co and licensed to Schering-Plough. Cedax had received marketing approval from the FDA in 1995.
Indicated for mild to moderate acute bacterial exacerbations of chronic bronchitis, acute bacterial otitis media, pharyngitis and tonsillitis, the once-a-day medication was launched by Schering-Plough in 1996.
Cooper Collins, president and CEO of Pernix, said: “We are excited about the acquisition of Cedax and the value it adds to our company. Annual product revenue for Cedax peaked over ten years ago while promoted by Schering-Plough.
“Since that peak it has not been promoted in first position and the sales have fallen drastically. Because Pernix has a history of reinvigorating established brands, we welcome the opportunity to grow the patent protected Cedax franchise for several years.”